Cargando…

Validity of new methods to evaluate renal function in cancer patients treated with cisplatin

PURPOSE: Creatinine clearance (Ccr) is used as a marker of renal function in cancer chemotherapy, but it is not correlated with glomerular filtration rate (GFR) after high-dose cisplatin treatment. In addition to Ccr, measured using 24-h urine collection (24-h Ccr) or Cockcroft–Gault formula (CGF),...

Descripción completa

Detalles Bibliográficos
Autores principales: Funakoshi, Yohei, Fujiwara, Yutaka, Kiyota, Naomi, Mukohara, Toru, Shimada, Takanobu, Toyoda, Masanori, Imamura, Yoshinori, Chayahara, Naoko, Tomioka, Hideo, Umezu, Michio, Otsuki, Naoki, Nibu, Ken-ichi, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747994/
https://www.ncbi.nlm.nih.gov/pubmed/26791871
http://dx.doi.org/10.1007/s00280-016-2966-1
_version_ 1782415044056711168
author Funakoshi, Yohei
Fujiwara, Yutaka
Kiyota, Naomi
Mukohara, Toru
Shimada, Takanobu
Toyoda, Masanori
Imamura, Yoshinori
Chayahara, Naoko
Tomioka, Hideo
Umezu, Michio
Otsuki, Naoki
Nibu, Ken-ichi
Minami, Hironobu
author_facet Funakoshi, Yohei
Fujiwara, Yutaka
Kiyota, Naomi
Mukohara, Toru
Shimada, Takanobu
Toyoda, Masanori
Imamura, Yoshinori
Chayahara, Naoko
Tomioka, Hideo
Umezu, Michio
Otsuki, Naoki
Nibu, Ken-ichi
Minami, Hironobu
author_sort Funakoshi, Yohei
collection PubMed
description PURPOSE: Creatinine clearance (Ccr) is used as a marker of renal function in cancer chemotherapy, but it is not correlated with glomerular filtration rate (GFR) after high-dose cisplatin treatment. In addition to Ccr, measured using 24-h urine collection (24-h Ccr) or Cockcroft–Gault formula (CGF), the Chronic Kidney Disease Epidemiology Collaboration (CKD–EPI) equation and the Japanese GFR estimation equation (the Japanese equation) have been recently developed to estimate GFR for predicting renal function. However, these equations remain to be evaluated, particularly in cancer patients treated with cisplatin. Therefore, we investigated the validity of these equations for predicting the GFR in cancer patients treated with cisplatin. METHODS: GFR was measured by inulin clearance (Cin) in 50 cancer patients and compared with GFR estimated by the CKD–EPI equation, the Japanese equation, and Ccr estimated by CGF or measured by 24-h Ccr before the first and third cisplatin-containing chemotherapy cycles (considered pretreatment and posttreatment, respectively). RESULTS: Before treatment, the CKD–EPI and the Japanese equations estimated GFR with higher accuracy than Ccr. Posttreatment bias values for GFR estimation using the CKD–EPI and the Japanese equations were lower than those for Ccr. The CKD–EPI and the Japanese equations were also more precise than Ccr. However, for patients with low renal function, these equations still overestimated Cin. CONCLUSION: The CKD–EPI and the Japanese equations estimated GFR with lower bias and higher precision than Ccr pre- and postcisplatin treatment. This study is registered at UMIN: 000002167.
format Online
Article
Text
id pubmed-4747994
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-47479942016-02-19 Validity of new methods to evaluate renal function in cancer patients treated with cisplatin Funakoshi, Yohei Fujiwara, Yutaka Kiyota, Naomi Mukohara, Toru Shimada, Takanobu Toyoda, Masanori Imamura, Yoshinori Chayahara, Naoko Tomioka, Hideo Umezu, Michio Otsuki, Naoki Nibu, Ken-ichi Minami, Hironobu Cancer Chemother Pharmacol Original Article PURPOSE: Creatinine clearance (Ccr) is used as a marker of renal function in cancer chemotherapy, but it is not correlated with glomerular filtration rate (GFR) after high-dose cisplatin treatment. In addition to Ccr, measured using 24-h urine collection (24-h Ccr) or Cockcroft–Gault formula (CGF), the Chronic Kidney Disease Epidemiology Collaboration (CKD–EPI) equation and the Japanese GFR estimation equation (the Japanese equation) have been recently developed to estimate GFR for predicting renal function. However, these equations remain to be evaluated, particularly in cancer patients treated with cisplatin. Therefore, we investigated the validity of these equations for predicting the GFR in cancer patients treated with cisplatin. METHODS: GFR was measured by inulin clearance (Cin) in 50 cancer patients and compared with GFR estimated by the CKD–EPI equation, the Japanese equation, and Ccr estimated by CGF or measured by 24-h Ccr before the first and third cisplatin-containing chemotherapy cycles (considered pretreatment and posttreatment, respectively). RESULTS: Before treatment, the CKD–EPI and the Japanese equations estimated GFR with higher accuracy than Ccr. Posttreatment bias values for GFR estimation using the CKD–EPI and the Japanese equations were lower than those for Ccr. The CKD–EPI and the Japanese equations were also more precise than Ccr. However, for patients with low renal function, these equations still overestimated Cin. CONCLUSION: The CKD–EPI and the Japanese equations estimated GFR with lower bias and higher precision than Ccr pre- and postcisplatin treatment. This study is registered at UMIN: 000002167. Springer Berlin Heidelberg 2016-01-20 2016 /pmc/articles/PMC4747994/ /pubmed/26791871 http://dx.doi.org/10.1007/s00280-016-2966-1 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Funakoshi, Yohei
Fujiwara, Yutaka
Kiyota, Naomi
Mukohara, Toru
Shimada, Takanobu
Toyoda, Masanori
Imamura, Yoshinori
Chayahara, Naoko
Tomioka, Hideo
Umezu, Michio
Otsuki, Naoki
Nibu, Ken-ichi
Minami, Hironobu
Validity of new methods to evaluate renal function in cancer patients treated with cisplatin
title Validity of new methods to evaluate renal function in cancer patients treated with cisplatin
title_full Validity of new methods to evaluate renal function in cancer patients treated with cisplatin
title_fullStr Validity of new methods to evaluate renal function in cancer patients treated with cisplatin
title_full_unstemmed Validity of new methods to evaluate renal function in cancer patients treated with cisplatin
title_short Validity of new methods to evaluate renal function in cancer patients treated with cisplatin
title_sort validity of new methods to evaluate renal function in cancer patients treated with cisplatin
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747994/
https://www.ncbi.nlm.nih.gov/pubmed/26791871
http://dx.doi.org/10.1007/s00280-016-2966-1
work_keys_str_mv AT funakoshiyohei validityofnewmethodstoevaluaterenalfunctionincancerpatientstreatedwithcisplatin
AT fujiwarayutaka validityofnewmethodstoevaluaterenalfunctionincancerpatientstreatedwithcisplatin
AT kiyotanaomi validityofnewmethodstoevaluaterenalfunctionincancerpatientstreatedwithcisplatin
AT mukoharatoru validityofnewmethodstoevaluaterenalfunctionincancerpatientstreatedwithcisplatin
AT shimadatakanobu validityofnewmethodstoevaluaterenalfunctionincancerpatientstreatedwithcisplatin
AT toyodamasanori validityofnewmethodstoevaluaterenalfunctionincancerpatientstreatedwithcisplatin
AT imamurayoshinori validityofnewmethodstoevaluaterenalfunctionincancerpatientstreatedwithcisplatin
AT chayaharanaoko validityofnewmethodstoevaluaterenalfunctionincancerpatientstreatedwithcisplatin
AT tomiokahideo validityofnewmethodstoevaluaterenalfunctionincancerpatientstreatedwithcisplatin
AT umezumichio validityofnewmethodstoevaluaterenalfunctionincancerpatientstreatedwithcisplatin
AT otsukinaoki validityofnewmethodstoevaluaterenalfunctionincancerpatientstreatedwithcisplatin
AT nibukenichi validityofnewmethodstoevaluaterenalfunctionincancerpatientstreatedwithcisplatin
AT minamihironobu validityofnewmethodstoevaluaterenalfunctionincancerpatientstreatedwithcisplatin